A Bruton's Tyrosine Kinase Inhibitor Prevents Antigen-Driven B Cell Activation In Vivo

被引：0
|
作者：
Benson, Micah [1 ]
Rodriguez, Varenka A. [1 ]
Andreyeva, Tatyana [1 ]
Keegan, Sean [1 ]
Springer, John R. [1 ]
Schnute, Mark E. [1 ]
Dunussi-Joannopoulos, Kyri [1 ]
Nickerson-Nutter, Cheryl L. [1 ]
Rankin, Andrew L. [1 ]
Ruzek, Melanie [1 ]
Douhan, John, III [1 ]
机构：
[1] Pfizer Inc, Cambridge, MA USA
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1758
引用
收藏
页码：S689 / S689
页数：1
相关论文
共 50 条
  • [41] Targeting Bruton's Tyrosine Kinase With Ibrutinib in B-Cell Malignancies
    Wang, Y.
    Zhang, L. L.
    Champlin, R. E.
    Wang, M. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (05) : 455 - 468
  • [42] Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies
    Marostica, Eleonora
    Sukbuntherng, Juthamas
    Loury, David
    de Jong, Jan
    de Trixhe, Xavier Woot
    Vermeulen, An
    De Nicolao, Giuseppe
    O'Brien, Susan
    Byrd, John C.
    Advani, Ranjana
    McGreivy, Jesse
    Poggesi, Italo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (01) : 111 - 121
  • [43] Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies
    Eleonora Marostica
    Juthamas Sukbuntherng
    David Loury
    Jan de Jong
    Xavier Woot de Trixhe
    An Vermeulen
    Giuseppe De Nicolao
    Susan O’Brien
    John C. Byrd
    Ranjana Advani
    Jesse McGreivy
    Italo Poggesi
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 111 - 121
  • [44] ANTIGEN-DRIVEN B-CELL DIFFERENTIATION INVIVO
    MCHEYZERWILLIAMS, MG
    MCLEAN, MJ
    LALOR, PA
    NOSSAL, GJV
    JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (01): : 295 - 307
  • [45] Bruton's Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR- and Nurselike Cell-Derived Activation of CLL Cells In Vitro and In Vivo
    Ponader, Sabine
    Buggy, Joseph
    O'Brien, Susan
    Wierda, William G.
    Keating, Michael
    Burger, Jan A.
    BLOOD, 2010, 116 (21) : 26 - 27
  • [46] Inhibitory-κB kinase (IKK)α is required for antigen-driven inflammation
    Johnson, Ella V. E.
    Lawrence, T.
    Seed, M. P.
    INFLAMMATION RESEARCH, 2006, 55 : S126 - S126
  • [47] Bruton Tyrosine Kinase Degraders in B-Cell Malignancies
    Huynh, Tiana
    Rodriguez-Rodriguez, Sonia
    Danilov, Alexey V.
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (05) : 619 - 626
  • [48] Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation
    Wang, Sheau-Pey
    Iwata, Shigeru
    Nakayamada, Shingo
    Niiro, Hiroaki
    Jabbarzadeh-Tabrizi, Siamak
    Kondo, Masahiro
    Kubo, Satoshi
    Yoshikawa, Maiko
    Tanaka, Yoshiya
    RHEUMATOLOGY, 2015, 54 (08) : 1488 - 1497
  • [49] Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib
    Dostalova, Hana
    Krystof, Vladimir
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (04)
  • [50] Mediation of transitional B cell maturation in the absence of functional Bruton’s tyrosine kinase
    Shalini Tanwar
    Atika Dhar
    Vineeth Varanasi
    Tapas Mukherjee
    Ramanamurthy Boppana
    Soumen Basak
    Vineeta Bal
    Anna George
    Satyajit Rath
    Scientific Reports, 7
12345